Lymphocytic interstitial pneumonia of common variable immunodeficiency

Area of Science:

• Immunology
• Pulmonology
• Pharmacology

Background:

• Common variable immunodeficiency (CVID) is a primary immunodeficiency often associated with lung complications.
• Lymphocytic interstitial pneumonitis (LIP) is a rare pulmonary manifestation of CVID, characterized by inflammatory infiltrates.
• Treatment options for CVID-associated LIP are limited, with varying degrees of efficacy.

Observation:

• A 27-year-old female patient with CVID and LIP presented with exertional dyspnea and radiographic infiltrates.
• Treatment with prednisone was initiated, and clinical and radiological parameters were monitored over 3.5 years.
• Changes in pulmonary function and radiographic findings paralleled the administered prednisone dosage.

Findings:

• Steroid therapy, specifically prednisone, demonstrated a beneficial effect in managing LIP in this CVID patient.
• The dose-dependent response to prednisone suggests a direct therapeutic role, excluding spontaneous remission.
• Treatment with steroids was deemed safe, as the frequency and severity of bronchial infections did not increase despite the absence of IgG replacement therapy.

Implications:

• Corticosteroids may represent a viable treatment option for lymphocytic interstitial pneumonitis in patients with common variable immunodeficiency.
• This case highlights the importance of considering steroid therapy for managing pulmonary manifestations in CVID.
• Further research is warranted to establish the long-term efficacy and safety of steroids in CVID-associated LIP.